Results 51 to 60 of about 291,220 (220)

Biomarkers of Complement and Platelet Activation are not correlated with the One or Twenty-Four Hours Corrected Count Increments in Prophylactically Platelet Transfused Hematological Patients: a Prospective Cohort Study

Platelets, 2022
Platelet transfusion refractoriness is a serious clinical concern that complicates the management of thrombocytopenic patients. Previous studies have suggested a potential role for both complement and platelet activation based on in vitro analyses of ...
Alexander Åkesson, Marcus Ljungkvist, Myriam Martin, Anna M. Blom, Jenny Klintman, Ulf Schött, Eva Zetterberg, Thomas Kander   +7 more
doaj   +1 more source

Analysis and prospect of platelet compatible transfusion

, 2022
Platelet compatible transfusion can effectively solve the immune mediated platelet transfusion refractoriness (PTR), save platelet resources and improve blood safety.
Zhixin ZHANG, Faming ZHU, Wei MAO
core   +1 more source

Long‐Term Outcomes After Elective Splenectomy for Haematological Disease: A 27‐Year Single‐Centre Study

ANZ Journal of Surgery, EarlyView.
Splenectomy is a safe and effective treatment option in selected patients with haematological disease, despite declining referrals over the last 27 years in the era of targeted therapies. Outcomes are favourable when performed laparoscopically and long‐term follow‐up demonstrates sustained haematologic benefit in surviving patients.
Salil Dutt Barrett, Anthony Downhill, Douglas Greer, William Stevenson, Ian Kerridge, Chris Ward, Matthew Greenwood, Naomi Mackinlay, Luke Coyle, Thomas J. Hugh   +9 more
wiley   +1 more source

Initial V‐A ECMO Flow‐Index and Its Association With Inflammation, Organ Failure, and Outcomes

Artificial Organs, EarlyView.
Higher initial V‐A ECMO flow‐index was associated with greater shock severity and independently associated with multi‐organ failure. Early hemolysis may partly contribute to this association, particularly in eCPR patients, whereas no significant indirect effect through IL‐6 was observed.
Kostiantyn Kozakov, Zdenek Provaznik, Alois Philipp, Maik Foltan, Christian Schach, Sergey Vasin, Andreas Keyser, Leopold Rupprecht, Christof Schmid, Simon Schopka   +9 more
wiley   +1 more source

Research progress on the pathogenesis, prevention and treatment of immune platelet transfusion refractoriness

Zhongguo shuxue zazhi
Platelet transfusion refractoriness (PTR) is one of the common problems in platelet transfusion, significantly impacting patient clinical outcomes and increasing the demand for allogeneic platelet transfusion.
LI Penghui, WU Chenggao, LE Aiping
doaj   +1 more source

Platelet Refractoriness and HLA Matched Platelets Slidedeck

Slide deck summarizing causes of platelet refractoriness and transfusion strategies for immune-refractoriness including HLA-matched versus crossmatch-compatible platelets.
David Allison (9094295)
core   +1 more source

Janus kinase inhibitors after ruxolitinib failure in myelofibrosis: A systematic review and pooled analysis of phase 3 efficacy and integrated safety across clinical trials and real‐world evidence

British Journal of Haematology, EarlyView.
Summary Ruxolitinib remains first‐line standard of care for symptomatic myelofibrosis, but resistance/intolerance develops in most patients. Three Janus kinase inhibitors (JAKis) have entered the post‐ruxolitinib space via distinct pivotal trials. We systematically searched prospective trials evaluating JAKi in refractory adults with myelofibrosis ...
Andrea Duminuco, Patrick Harrington, Elena Torre, Hillary Catellani, Novella Pugliese, Matteo Pacilli, Annalisa Santisi, Arianna Sbriglione, Giuseppe A. Palumbo   +8 more
wiley   +1 more source

Distinct clinical and genetic characteristics of myelodysplastic syndrome in younger patients

British Journal of Haematology, EarlyView.
Summary Myelodysplastic neoplasms (formerly myelodysplastic syndromes, MDS) are heterogeneous clonal haematological malignancies that primarily affect the elderly, though a notable proportion of patients are diagnosed at younger ages. We retrospectively analysed 1437 patients diagnosed or treated at Asan Medical Center between 1989 and 2022, comparing ...
Hyunkyung Park, Eun‐Ji Choi, Young‐Uk Cho, Yunsuk Choi, Han‐Seung Park, Jung‐Hee Lee, Joon Young Hur, Jisu Jeong, Seungah Cha, Yueun Lee, Young‐Shin Lee, Young‐Ah Kang, Mijin Jeon, Ji Min Woo, Hyeran Kang, Je‐Hwan Lee   +15 more
wiley   +1 more source

Comparison of a therapeutic platelet transfusion strategy to a prophylactic platelet transfusion strategy in autologous stem cell transplant (ASCT), a single centre experience

, 2021
In 2016, the British Journal of Haematology platelet transfusion guideline suggests not giving prophylactic platelet transfusions to well ASCT patients with no bleeding [1].
Hickey, B, Cochrane, T, McKeough, N, Savoia, C, Beth Hickey, Tara Cochrane, Nicholas McKeough, Camille Savoia   +7 more
core   +1 more source

Real‐world outcomes of ide‐cel and cilta‐cel in relapsed/refractory multiple myeloma: A nationwide, retrospective analysis in Austria

British Journal of Haematology, EarlyView.
Summary B‐cell maturation antigen‐directed chimeric antigen receptor (CAR) T cells have revolutionized the treatment of relapsed/refractory multiple myeloma. However, no randomized head‐to‐head comparison of idecabtagene vicleucel (ide‐cel) and ciltacabtagene autoleucel (cilta‐cel) is available, and real‐world data suggest differences in efficacy and ...
Irene Strassl, Alexander Nikoloudis, Lina Zoe Ruesing, Thomas Melchardt, Michael Leisch, Eduard Schulz, Annkristin Heine, Peter Neumeister, Normann Steiner, Dominik Wolf, Wolfgang Willenbacher, Petra Pichler‐Izmir, Theresa Lentner, Johannes Clausen, Veronika Buxhofer‐Ausch, Sigrid Machherndl‐Spandl, Olga Saini, Dagmar Wipplinger, Holger Rumpold, Nina Worel, Werner Rabitsch, Axel Schulenburg, Hermine Agis, Maria‐Theresa Krauth   +23 more
wiley   +1 more source